12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Via Pharmaceuticals, Roche preclinical data

In rats, Via's Compound X showed a significant dose-dependent inhibition of body weight gain and reduction in fat pad size. The small molecule inhibitor of diacylglycerol O-acyltransferase-1...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >